+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 20Years - 90Years
All Genders
ID06594744

Comparing Endoscopic Variceal Ligation and Carvedilol to Prevent First Esophageal Variceal Bleeding in Adults with Hepatocellular Carcinoma

Led by Taipei Veterans General Hospital, Taiwan · Updated on 2025-02-13

120

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to compare two methods to prevent the first esophageal variceal bleeding EVB in patients with hepatocellular carcinoma HCC who have high-risk esophageal varices EVs. The study evaluates the effectiveness and safety of endoscopic variceal ligation EVL versus carvedilol, a medication, in reducing the risk of EVB in this patient group. It also investigates medical problems participants may experience during treatment and compares outcomes such as bleeding, liver complications, overall survival, and side effects. Participants will be randomly assigned to one of two groups. One group will undergo EVL, a procedure performed every 3 to 4 weeks until varices are eradicated, followed by regular endoscopic surveillance initially every three months, then every six months, and finally annually. The other group will take carvedilol daily, starting at 6.25 mg and increasing to 12.5 mg if tolerated, with dosing adjustments depending on blood pressure and heart rate. This open-label trial monitors both treatment approaches over time. During the study, participants will visit the clinic every 2 to 3 months for checkups and tests. They will keep a diary recording vital signs such as blood pressure and heart rate, along with any symptoms. Researchers will measure the occurrence of esophageal variceal bleeding over three years, as well as other gastrointestinal bleeding, liver complications, survival, and adverse events. The study includes ongoing safety monitoring and assessments throughout the trial period.

CONDITIONS

Brief Title

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

Research Team

T

Tsung-Chieh Yang, MD

M

Ming-Chih Hou, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here